JP2014158485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158485A5 JP2014158485A5 JP2014080445A JP2014080445A JP2014158485A5 JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5 JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- erbb3
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 329
- 150000001413 amino acids Chemical class 0.000 claims 31
- 238000012217 deletion Methods 0.000 claims 12
- 230000037430 deletion Effects 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 12
- 238000007792 addition Methods 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000006229 amino acid addition Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477089P | 2011-04-19 | 2011-04-19 | |
| US61/477,089 | 2011-04-19 | ||
| US201161539297P | 2011-09-26 | 2011-09-26 | |
| US61/539,297 | 2011-09-26 | ||
| US201161558192P | 2011-11-10 | 2011-11-10 | |
| US61/558,192 | 2011-11-10 | ||
| US201261619244P | 2012-04-02 | 2012-04-02 | |
| US61/619,244 | 2012-04-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Division JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014158485A JP2014158485A (ja) | 2014-09-04 |
| JP2014158485A5 true JP2014158485A5 (2) | 2015-06-11 |
| JP6214453B2 JP6214453B2 (ja) | 2017-10-18 |
Family
ID=47021510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
| JP2014080445A Expired - Fee Related JP6214453B2 (ja) | 2011-04-19 | 2014-04-09 | 単一特異性および二重特異性抗ｉｇｆ‐１ｒ抗体および抗ｅｒｂｂ３抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8476409B2 (2) |
| EP (2) | EP3214096A3 (2) |
| JP (2) | JP5588086B2 (2) |
| KR (2) | KR20140138353A (2) |
| CN (2) | CN105884900A (2) |
| AU (2) | AU2012245491C1 (2) |
| BR (1) | BR112013027021A2 (2) |
| CA (1) | CA2833643A1 (2) |
| DK (1) | DK2699602T3 (2) |
| ES (1) | ES2625818T3 (2) |
| HK (1) | HK1223383A1 (2) |
| HR (1) | HRP20170713T1 (2) |
| HU (1) | HUE034276T2 (2) |
| IL (1) | IL228957A0 (2) |
| MX (2) | MX346486B (2) |
| PL (1) | PL2699602T3 (2) |
| PT (1) | PT2699602T (2) |
| SI (1) | SI2699602T1 (2) |
| TW (1) | TWI631136B (2) |
| WO (1) | WO2012145507A2 (2) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| CA2792327C (en) | 2010-03-11 | 2019-09-24 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| BR112014024494A2 (pt) * | 2012-04-02 | 2017-08-08 | Merrimack Pharmaceuticals Inc | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2975829A1 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| EP3134438B1 (en) * | 2014-04-25 | 2020-09-30 | Pierre Fabre Medicament | Igf-1r antibody and its use as addressing vehicle for the treatment of cancer |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP3303398A1 (en) * | 2015-05-29 | 2018-04-11 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| MX385425B (es) | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| MX382522B (es) | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| WO2017127545A1 (en) | 2016-01-19 | 2017-07-27 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
| EA201891732A1 (ru) * | 2016-02-02 | 2019-02-28 | Кадмон Корпорейшн, Ллк | Биспецифичные связывающие белки для pd-l1 и kdr |
| US10723857B1 (en) * | 2016-04-15 | 2020-07-28 | United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration | Polyimide aerogels with reduced shrinkage from isothermal aging |
| WO2018045256A1 (en) * | 2016-09-02 | 2018-03-08 | Merrimack Pharmaceuticals, Inc. | Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer |
| JP6825284B2 (ja) * | 2016-09-21 | 2021-02-03 | カシオ計算機株式会社 | イメージ作成装置、イメージ作成方法、及び、プログラム |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| LT3628049T (lt) * | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US10654944B2 (en) | 2018-04-10 | 2020-05-19 | Y-Biologics Inc. | Cell engaging binding molecules |
| US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CA3109361A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| US11518792B2 (en) | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN120924491A (zh) | 2019-06-21 | 2025-11-11 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| BR112022003663A2 (pt) | 2019-08-28 | 2022-05-24 | Horizon Therapeutics Ireland Dac | Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted) |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| CN118043351A (zh) * | 2021-08-31 | 2024-05-14 | 上海医药集团股份有限公司 | 靶向Siglec15的抗原结合蛋白及其用途 |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| WO2023201311A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL126303A (en) | 1996-03-27 | 2002-05-23 | Genentech Inc | ErbB3 ANTIBODIES |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| BRPI0116728B1 (pt) * | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| KR101516823B1 (ko) * | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| AU2007353412A1 (en) * | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
| CA2697922A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| TW201100543A (en) * | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| JP5752687B2 (ja) | 2009-08-21 | 2015-07-22 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| CN102884085B (zh) | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
| NZ607337A (en) * | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| BR112014024494A2 (pt) | 2012-04-02 | 2017-08-08 | Merrimack Pharmaceuticals Inc | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
| CA2975829A1 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| WO2017127545A1 (en) * | 2016-01-19 | 2017-07-27 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
-
2012
- 2012-04-19 CN CN201510472421.9A patent/CN105884900A/zh active Pending
- 2012-04-19 PT PT127739506T patent/PT2699602T/pt unknown
- 2012-04-19 EP EP17158234.9A patent/EP3214096A3/en not_active Withdrawn
- 2012-04-19 ES ES12773950.6T patent/ES2625818T3/es active Active
- 2012-04-19 CA CA2833643A patent/CA2833643A1/en not_active Abandoned
- 2012-04-19 US US13/451,135 patent/US8476409B2/en active Active
- 2012-04-19 KR KR1020147031817A patent/KR20140138353A/ko not_active Ceased
- 2012-04-19 EP EP12773950.6A patent/EP2699602B1/en active Active
- 2012-04-19 CN CN201280028639.XA patent/CN103703026B/zh not_active Expired - Fee Related
- 2012-04-19 MX MX2016000234A patent/MX346486B/es unknown
- 2012-04-19 BR BR112013027021A patent/BR112013027021A2/pt not_active Application Discontinuation
- 2012-04-19 DK DK12773950.6T patent/DK2699602T3/en active
- 2012-04-19 WO PCT/US2012/034244 patent/WO2012145507A2/en not_active Ceased
- 2012-04-19 JP JP2014506549A patent/JP5588086B2/ja not_active Expired - Fee Related
- 2012-04-19 SI SI201230955A patent/SI2699602T1/sl unknown
- 2012-04-19 AU AU2012245491A patent/AU2012245491C1/en not_active Ceased
- 2012-04-19 HU HUE12773950A patent/HUE034276T2/en unknown
- 2012-04-19 PL PL12773950T patent/PL2699602T3/pl unknown
- 2012-04-19 KR KR1020137030562A patent/KR101517320B1/ko not_active Expired - Fee Related
- 2012-04-19 HR HRP20170713TT patent/HRP20170713T1/hr unknown
- 2012-04-19 MX MX2013012201A patent/MX336197B/es unknown
- 2012-04-19 TW TW101114063A patent/TWI631136B/zh not_active IP Right Cessation
-
2013
- 2013-02-27 US US13/778,984 patent/US9556274B2/en not_active Expired - Fee Related
- 2013-10-17 IL IL228957A patent/IL228957A0/en unknown
-
2014
- 2014-04-09 JP JP2014080445A patent/JP6214453B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,344 patent/US9527914B2/en not_active Expired - Fee Related
-
2016
- 2016-08-26 US US15/248,562 patent/US9938346B2/en active Active
- 2016-10-10 HK HK16111680.4A patent/HK1223383A1/zh unknown
-
2017
- 2017-08-16 AU AU2017216490A patent/AU2017216490A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014158485A5 (2) | ||
| JP2020124209A5 (2) | ||
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP2019500862A5 (2) | ||
| JP2021042257A5 (2) | ||
| JP2019525738A5 (2) | ||
| JP2016536322A5 (2) | ||
| JP2017511130A5 (2) | ||
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| JP2017504578A5 (2) | ||
| JP2016514463A5 (2) | ||
| JP2020517287A5 (2) | ||
| JP2013535191A5 (2) | ||
| BR112020000762A2 (pt) | anticorpo de dupla especificidade, moléculas polipeptídicas, ácido nucleico, célula hospedeira, composição farmacêutica e método de tratamento de uma doença ou condição | |
| JP2017529067A5 (2) | ||
| RU2019102008A (ru) | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| CA2970800A1 (en) | Monomeric fc domains | |
| JP2020524510A5 (2) | ||
| JP2018526981A5 (2) | ||
| RU2015111708A (ru) | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение | |
| JP2011505810A5 (2) | ||
| JP2020515277A5 (2) | ||
| JP2017534296A5 (2) |